---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-206368"
form_type: "8-K"
ticker: "RARE"
cik: "0001515673"
company_name: "Ultragenyx Pharmaceutical Inc."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:20:47.706729+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ultragenyx Q1 revenue $136M, net loss $1.84/share; reaffirms 2026 guidance; GTX-102 Phase 3 data H2 2026

## Summary
- Total revenue $136M (Q1 2025: $139M); Crysvita $93M, Dojolvi $18M, Evkeeza $18M, Mepsevii $7M.
- Net loss $185M ($1.84/share) vs $151M ($1.57/share); operating expenses $305M including $30M restructuring.
- Reaffirms 2026 total revenue guidance $730M-$760M; combined R&D and SG&A expenses flat to slightly down vs 2025.
- DTX401 BLA for GSDIa granted Priority Review; PDUFA Aug 23, 2026. UX111 BLA resubmitted for MPS IIIA; PDUFA Sept 19, 2026.
- GTX-102 Angelman Phase 3 data expected H2 2026; DTX301 Phase 3 showed significant ammonia reduction.

## SEC filing metadata
- accession: 0001193125-26-206368
- form_type: 8-K
- ticker: RARE
- cik: 0001515673
- company_name: Ultragenyx Pharmaceutical Inc.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000119312526206368/0001193125-26-206368-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000119312526206368/rare-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-206368
- JSON: https://secwatch.observer/filing/0001193125-26-206368.json
- Plain text: https://secwatch.observer/filing/0001193125-26-206368.txt

## Source-grounded claims
- claim_id: 3003d5773ec252029fe857f6d945db37c1772416
  claim: Ultragenyx Pharmaceutical Inc. reported the quarter ended March 31, 2026 results: revenue $136 million. Guidance reaffirmed.
  evidence_excerpt: Higa ir@ultragenyx.com Media Jess Rowlands media@ultragenyx.com Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update First quarter total revenue of $136 million, Crysvita® revenue of $93 million and Dojolvi® revenue of $18 million Reaffirm 2026 financial guidance, including total revenue of $730 million to $760 million and combined R&D
  evidence_url: https://www.sec.gov/Archives/edgar/data/1515673/000119312526206368/0001193125-26-206368-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.